Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.860 -0.220 (-2.18%)
Streaming Delayed Price Updated: 1:52 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 424,908
Open 10.49
Bid (Size) 9.840 (100)
Ask (Size) 9.880 (500)
Prev. Close 10.08
Today's Range 9.720 - 10.96
52wk Range 4.320 - 18.77
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones
Prothena reports Q3 2025 earnings, provides updates on its neurodegenerative disease pipeline, and reaffirms strong cash position. 
Via Chartmill
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire

Performance

YTD
-27.9%
-27.9%
1 Month
-3.0%
-3.0%
3 Month
+27.7%
+27.7%
6 Month
+38.9%
+38.9%
1 Year
-46.3%
-46.3%

More News

Read More
Earnings Scheduled For November 6, 2025
Via Benzinga
Prothena to Report Third Quarter 2025 Financial Results on November 6
From Prothena Corporation plc
Via Business Wire
9 Analysts Assess Prothena Corp: What You Need To Know
Via Benzinga
Earnings Scheduled For August 4, 2025
Via Benzinga
A Glimpse of Prothena Corp's Earnings Potential
Via Benzinga
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
Via Benzinga
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Via Benzinga
What 4 Analyst Ratings Have To Say About Prothena Corp
Via Benzinga
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
From Prothena Corporation plc
Via Business Wire
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful
Via Stocktwits
Topics Earnings
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Prothena Q2 Revenue Drops 97%
Via The Motley Fool
Topics Intellectual Property
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Second Quarter 2025 Financial Results on August 4
From Prothena Corporation plc
Via Business Wire
8 Analysts Assess Prothena Corp: What You Need To Know
Via Benzinga
Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast
Via Stocktwits
Topics Workforce
Prothena Announces Corporate Restructuring
From Prothena Corporation plc
Via Business Wire
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
From Prothena Corporation plc
Via Business Wire
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga

Frequently Asked Questions

Is Prothena Corporation plc - Ordinary Shares publicly traded?
Yes, Prothena Corporation plc - Ordinary Shares is publicly traded.
What exchange does Prothena Corporation plc - Ordinary Shares trade on?
Prothena Corporation plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Prothena Corporation plc - Ordinary Shares?
The ticker symbol for Prothena Corporation plc - Ordinary Shares is PRTA on the Nasdaq Stock Market
What is the current price of Prothena Corporation plc - Ordinary Shares?
The current price of Prothena Corporation plc - Ordinary Shares is 9.860
When was Prothena Corporation plc - Ordinary Shares last traded?
The last trade of Prothena Corporation plc - Ordinary Shares was at 11/07/25 01:52 PM ET
What is the market capitalization of Prothena Corporation plc - Ordinary Shares?
The market capitalization of Prothena Corporation plc - Ordinary Shares is 444.17M
How many shares of Prothena Corporation plc - Ordinary Shares are outstanding?
Prothena Corporation plc - Ordinary Shares has 444M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.